Literature DB >> 16387223

Empiric acyclovir is infrequently initiated in the emergency department to patients ultimately diagnosed with encephalitis.

Peter C Benson1, Stuart P Swadron.   

Abstract

STUDY
OBJECTIVE: We evaluate the frequency of empiric acyclovir administration to patients in the emergency department (ED) who are ultimately diagnosed with encephalitis.
METHODS: We conducted an explicit retrospective medical record review of consecutive patients discharged with a final diagnosis of herpes simplex encephalitis or viral encephalitis not otherwise specified for the period 1993 to 2003. The frequency of ED administration of empiric acyclovir was measured for patients who met the inclusion criteria of fever, neuropsychiatric abnormality, and cerebrospinal fluid pleocytosis with a negative Gram's stain result in the ED.
RESULTS: Of the 90 patients reviewed, 24 (27%) met the inclusion criteria of fever, neuropsychiatric abnormality, and cerebrospinal fluid pleocytosis with a negative Gram's stain result in the ED. Of these 24 patients, 7 (29%) received empiric acyclovir in the ED, 6 (86%) patients after cerebrospinal fluid results were available, with a median time to administration of 1.5 hours (95% confidence interval [CI] 0 to 3.1 hours). The remaining 17 (71%) patients did not receive acyclovir in the ED, with median times of 16 hours (95% CI 7.5 to 44 hours) before initiation of acyclovir in inpatient settings.
CONCLUSION: The majority of patients in our institution who were ultimately diagnosed with encephalitis did not receive empiric acyclovir in the ED, despite clinical presentations consistent with encephalitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16387223     DOI: 10.1016/j.annemergmed.2005.07.019

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  5 in total

1.  Epstein-Barr virus encephalitis presenting as cerebellar hemorrhage.

Authors:  Shyam Sabat; Amit Agarwal; Thomas Zacharia; Samuel Labib; Jacob Yousef
Journal:  Neuroradiol J       Date:  2015-10-16

2.  Diagnostic delay in a case of herpes simplex encephalitis.

Authors:  Zaid Shalchi; Alan Bennett; David Hargroves; James Nash
Journal:  BMJ Case Rep       Date:  2009-06-01

Review 3.  Herpes Simplex Encephalitis: an Update.

Authors:  John W Gnann; Richard J Whitley
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

4.  Results of a multinational study suggest the need for rapid diagnosis and early antiviral treatment at the onset of herpetic meningoencephalitis.

Authors:  Hakan Erdem; Yasemin Cag; Derya Ozturk-Engin; Sylviane Defres; Selcuk Kaya; Lykke Larsen; Mario Poljak; Bruno Barsic; Xavier Argemi; Signe Maj Sørensen; Anne Lisbeth Bohr; Pierre Tattevin; Jesper Damsgaard Gunst; Lenka Baštáková; Matjaž Jereb; Isik Somuncu Johansen; Oguz Karabay; Abdullah Umut Pekok; Oguz Resat Sipahi; Mahtab Chehri; Guillaume Beraud; Ghaydaa Shehata; Rosa Fontana Del Vecchio; Mauro Maresca; Hasan Karsen; Gonul Sengoz; Mustafa Sunbul; Gulden Yilmaz; Hava Yilmaz; Ahmad Sharif-Yakan; Souha Shararah Kanj; Emine Parlak; Filiz Pehlivanoglu; Fatime Korkmaz; Suheyla Komur; Sukran Kose; Mehmet Ulug; Sibel Bolukcu; Seher Ayten Coskuner; Nevin Ince; Yasemin Akkoyunlu; Gulistan Halac; Elif Sahin-Horasan; Hulya Tireli; Gamze Kilicoglu; Akram Al-Mahdawi; Salih Atakan Nemli; Asuman Inan; Seniha Senbayrak; Jean Paul Stahl; Haluk Vahaboglu
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

5.  Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy.

Authors:  John W Gnann; Birgit Sköldenberg; John Hart; Elisabeth Aurelius; Silvia Schliamser; Marie Studahl; Britt-Marie Eriksson; Daniel Hanley; Fred Aoki; Alan C Jackson; Paul Griffiths; Lil Miedzinski; Diane Hanfelt-Goade; Daniel Hinthorn; Clas Ahlm; Allen Aksamit; Salvador Cruz-Flores; Ilet Dale; Gretchen Cloud; Penelope Jester; Richard J Whitley
Journal:  Clin Infect Dis       Date:  2015-05-08       Impact factor: 9.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.